Can an inhaled therapy replace a daily pill for PAH?
NCT ID NCT07759804
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial tests whether adults with pulmonary arterial hypertension (PAH) can safely switch from selexipag, a pill taken by mouth, to LIQ861, an inhaled form of treprostinil. Participants stop selexipag on day one and start taking LIQ861 four times a day using a handheld inhaler, with doses adjusted based on how well they tolerate it. The study tracks side effects, walking distance, a blood marker of heart strain, and reported symptoms over 16 weeks. The goal is to see if this switch is a safe and tolerable option for managing PAH.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LIQ861 (treprostinil) inhalation powder, taken four times daily via a handheld dry powder inhaler
- What this could lead to
- If successful, this could offer people with PAH a new way to manage their condition by switching from a daily pill to an inhaled treatment, potentially with fewer side effects.
- What could go wrong
- This is a small, open-label study (20 people) focused on safety and tolerability, not effectiveness. It may not show clear benefits, and some people may not tolerate the switch or the inhaled drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Southeastern Cardiology Associates
Columbus, Georgia, 31904, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check
- New hope for PAH patients: Extended-Release tacrolimus enters phase 3 trial